Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Colitis Overview 10 Therapeutics Development 11 Pipeline Products for Colitis - Overview 11 Pipeline Products for Colitis - Comparative Analysis 12 Colitis - Therapeutics under Development by Companies 13 Colitis - Therapeutics under Investigation by Universities/Institutes 15 Colitis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Colitis - Products under Development by Companies 19 Colitis - Products under Investigation by Universities/Institutes 20 Colitis - Companies Involved in Therapeutics Development 21 Aerpio Therapeutics, Inc. 21 Akebia Therapeutics, Inc. 22 Amorepacific Corporation 23 Bayer AG 24 Bristol-Myers Squibb Company 25 Cosmo Pharmaceuticals S.p.A 26 Dr. Falk Pharma GmbH 27 EA Pharma Co Ltd 28 Euroscreen S.A. 29 Genfit SA 30 Immuron Limited 31 Innate Pharma S.A. 32 Peptinov SAS 33 Pfizer Inc. 34 Prokarium Limited 35 RDD Pharma Ltd. 36 Saniona AB 37 Synovo GmbH 38 Colitis - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 AcTMP-1 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AKB-4924 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AKB-6899 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 AN-346 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Antibody for Colitis - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 APY-0201 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BC-1215 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 BMS-986104 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 budesonide - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Clostridium difficile vaccine - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 CSY-0073 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 elafibranor - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 ESN-601 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 IMM-124E - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 IPH-33 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 mesalamine - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 NK-007 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 PAC-14028 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 PF-06425090 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 PPV-06 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 RDD-2007 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 rifamycin CR - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 RP-182 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Small Molecule for Colitis - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Vaccine to Target IL12 and IL23 for Colitis - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Vaccine to Target IL23 for Colitis - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 ZK-216348 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Colitis - Dormant Projects 96 Colitis - Discontinued Products 99 Colitis - Product Development Milestones 100 Featured News & Press Releases 100 Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX 100 Jul 11, 2013: Mylan Confirms First-to-File Patent Challenge Relating to CANASA 100 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102

List of Tables Number of Products under Development for Colitis, H2 2016 11 Number of Products under Development for Colitis - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016 21 Colitis - Pipeline by Akebia Therapeutics, Inc., H2 2016 22 Colitis - Pipeline by Amorepacific Corporation, H2 2016 23 Colitis - Pipeline by Bayer AG, H2 2016 24 Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016 25 Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016 26 Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 27 Colitis - Pipeline by EA Pharma Co Ltd, H2 2016 28 Colitis - Pipeline by Euroscreen S.A., H2 2016 29 Colitis - Pipeline by Genfit SA, H2 2016 30 Colitis - Pipeline by Immuron Limited, H2 2016 31 Colitis - Pipeline by Innate Pharma S.A., H2 2016 32 Colitis - Pipeline by Peptinov SAS, H2 2016 33 Colitis - Pipeline by Pfizer Inc., H2 2016 34 Colitis - Pipeline by Prokarium Limited, H2 2016 35 Colitis - Pipeline by RDD Pharma Ltd., H2 2016 36 Colitis - Pipeline by Saniona AB, H2 2016 37 Colitis - Pipeline by Synovo GmbH, H2 2016 38 Assessment by Monotherapy Products, H2 2016 39 Number of Products by Stage and Target, H2 2016 41 Number of Products by Stage and Mechanism of Action, H2 2016 43 Number of Products by Stage and Route of Administration, H2 2016 45 Number of Products by Stage and Molecule Type, H2 2016 47 Colitis - Dormant Projects, H2 2016 96 Colitis - Dormant Projects (Contd..1), H2 2016 97 Colitis - Dormant Projects (Contd..2), H2 2016 98 Colitis - Discontinued Products, H2 2016 99 List of Figures Number of Products under Development for Colitis, H2 2016 11 Number of Products under Development for Colitis - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Products, H2 2016 18 Assessment by Monotherapy Products, H2 2016 39 Number of Products by Top 10 Targets, H2 2016 40 Number of Products by Stage and Top 10 Targets, H2 2016 40 Number of Products by Top 10 Mechanism of Actions, H2 2016 42 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 42 Number of Products by Routes of Administration, H2 2016 44 Number of Products by Stage and Routes of Administration, H2 2016 44 Number of Products by Top 10 Molecule Types, H2 2016 46 Number of Products by Stage and Top 10 Molecule Types, H2 2016 46

Aerpio Therapeutics, Inc. Akebia Therapeutics, Inc. Amorepacific Corporation Bayer AG Bristol-Myers Squibb Company Cosmo Pharmaceuticals S.p.A Dr. Falk Pharma GmbH EA Pharma Co Ltd Euroscreen S.A. Genfit SA Immuron Limited Innate Pharma S.A. Peptinov SAS Pfizer Inc. Prokarium Limited RDD Pharma Ltd. Saniona AB Synovo GmbH